US 12,404,345 B2
Humanized antibodies against iRHOM2
Matthias Schneider, Neufarn (DE); Jens Ruhe, Planegg (DE); Gisela Weskamp, Eastchester, NY (US); and Carl Blobel, Eastchester, NY (US)
Assigned to SciRhom GmbH, Planegg (DE); and New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery, New York, NY (US)
Filed by SCIRHOM GMBH, Planegg (DE); and NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY, New York, NY (US)
Filed on Dec. 19, 2024, as Appl. No. 18/988,307.
Application 18/988,307 is a division of application No. 18/279,715, previously published as PCT/EP2022/054853, filed on Feb. 25, 2022.
Claims priority of application No. 21160030 (EP), filed on Mar. 1, 2021; and application No. 21165682 (EP), filed on Mar. 29, 2021.
Prior Publication US 2025/0145734 A1, May 8, 2025
Int. Cl. C07K 16/40 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01)
CPC C07K 16/40 (2013.01) [A61P 37/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01)] 24 Claims
 
1. A humanized antibody that binds human iRhom2, or an iRhom2-binding fragment thereof, wherein the antibody comprises three heavy chain and three light chain complementarity determining regions (CDRs) comprising:
an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10;
an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 11;
an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 12;
an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 14;
an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 15; and
an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 16.